These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18513976)

  • 1. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
    Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
    Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
    Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
    Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
    Khier S; Deleuze-Masquéfa C; Moarbess G; Gattacceca F; Margout D; Solassol I; Cooper JF; Pinguet F; Bonnet PA; Bressolle FM
    Eur J Pharm Sci; 2010 Jan; 39(1-3):23-9. PubMed ID: 19854270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives.
    Zarranz B; Jaso A; Aldana I; Monge A
    Bioorg Med Chem; 2004 Jul; 12(13):3711-21. PubMed ID: 15186857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.
    Yoo HW; Suh ME; Park SW
    J Med Chem; 1998 Nov; 41(24):4716-22. PubMed ID: 9822542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro antitumor activity of new quinoxaline derivatives.
    Corona P; Carta A; Loriga M; Vitale G; Paglietti G
    Eur J Med Chem; 2009 Apr; 44(4):1579-91. PubMed ID: 18774202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imidazo[1,2-
    Chouchou A; Patinote C; Cuq P; Bonnet PA; Deleuze-Masquéfa C
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30445763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
    Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
    Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
    Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
    J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
    Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
    Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
    Xue N; Yang X; Wu R; Chen J; He Q; Yang B; Lu X; Hu Y
    Bioorg Med Chem; 2008 Mar; 16(5):2550-7. PubMed ID: 18226907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activities of pyrazolo[3,4-g]quinoxaline derivatives.
    Gavara L; Saugues E; Alves G; Debiton E; Anizon F; Moreau P
    Eur J Med Chem; 2010 Nov; 45(11):5520-6. PubMed ID: 20864224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Design and synthesis of quinoxaline derivatives and their antitumor activities].
    Zhao CH; Chen Y; Ding J; Duan WH
    Yao Xue Xue Bao; 2005 Sep; 40(9):814-9. PubMed ID: 16342683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
    Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
    J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS.
    Khier S; Moarbess G; Deleuze-Masquefa C; Solassol I; Margout D; Pinguet F; Bonnet PA; Bressolle FM
    J Sep Sci; 2009 May; 32(9):1363-73. PubMed ID: 19399864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
    Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
    Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.